Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Change of Auditor

5th Nov 2025 07:01

RNS Number : 1927G
Cambridge Cognition Holdings PLC
05 November 2025
 

5 November 2025

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Change of Auditor

 

Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces the appointment of Cooper Parry Group Limited ("Cooper Parry") as the Company's new external auditor following a competitive audit tender process. The Company also announces that as a result of the process Crowe UK LLP ("Crowe") has resigned as the Company's auditor.

 

Cooper Parry will conduct the audit of the Company's financial statements for the financial period to 31 December 2025 and a proposal to re-appoint Cooper Parry as auditors of the Company will be subject to the approval of shareholders at the 2026 Annual General Meeting.

 

Crowe has been the auditor for the Company since 2023. Crowe has confirmed to the Company that there are no matters connected with their ceasing to hold office that need to be brought to the attention of the members or creditors of the Company for the purposes of section 519 of the Companies Act 2006.

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Rob Baker, Chief Executive Officer

Ronald Openshaw, Chief Financial Officer

 

Tel: 01223 810700 

[email protected] 

Panmure Liberum Limited (NOMAD and Joint Broker)

Will Goode / Mark Rogers / Freddy Crossley

Rupert Dearden 

Tel: 020 7886 2968

(Corporate Finance)

(Corporate Broking)

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / Amber Higgs

 

Tel: 020 3903 7715 

 

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

· Clinical Studies for new pharmaceuticals;

· Academic Research for scientists to understand CNS disorders;

· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPKZMGMRDZGKZM

Related Shares:

Cambridge Cog
FTSE 100 Latest
Value9,698.37
Change-109.31